CoQ10
Phase 1Small molecule
CoQ10 is one of 38 small molecule programs targeting Oxidative Stress. It is currently in Phase 1.
2
Indications
7
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
51 competitors in Oxidative Stress
#DrugCompanyPhaseTrials
1Amidate
PfizerApproved
Actos
TakedaApproved
Precose
BayerApproved
Amaryl
SanofiApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Zocor
OOrganon and Co
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oxidative Stress1 trial
Breast Cancer1 trial
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
Completed·—·Phase 1·NCT00976131·7 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CoQ10. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details